Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|March 22, 2017
Adverse Events in Cancer ImmunotherapyNoha Abdel-Wahab, Anas Alshawa, Maria E Suarez-Almazor
European Journal of Pediatric Surgery Reports|September 5, 2022
Esophageal Perforation into the Pericardium in a 3-Year-Old Child with Esophageal Stricture: A Rare Complication Following Esophageal DilatationAbdulrahman Nasser, Raif Nassir, Muhammad Younas Awan, et al.
Journal for Immunotherapy of Cancer|January 11, 2021
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II studyNazanin Majd, Steven G Waguespack, Filip Janku, et al.
Investigational New Drugs|February 13, 2021
Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trialAnas Alshawa, Alexandra Perez Cadena, Bettzy Stephen, et al.
Journal for Immunotherapy of Cancer|April 19, 2020
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumorsCoya Tapia, Phyu P Aung, Sinchita Roy-Chowdhuri, et al.
The Oncologist|March 26, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignanciesJibran Ahmed, Anne Knisely, Carlos Torrado, et al.
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
Investigational New Drugs|October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of conceptRivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic MelanomaMohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Pageof 2